Laura Brunner
Papers
1
Total Citations
33
H-Index
1
About
Laura Brunner is a translational scientist whose work bridges clinical biomarkers and therapeutic development, with a particular focus on bone metabolism and musculoskeletal disorders. Her most cited paper, a 2009 study on the "fit-for-purpose" validation and application of C-terminal telopeptides of Type 1 collagen (CTX-1) as a biomarker in denosumab clinical trials, has garnered 33 citations and exemplifies her expertise in rigorous biomarker methodology. This contribution was pivotal in establishing CTX-1 as a reliable pharmacodynamic marker for denosumab, a monoclonal antibody used to treat osteoporosis and bone metastases, thereby supporting regulatory decisions and clinical trial design. Brunner’s work demonstrates a deep commitment to ensuring that biomarkers are not only scientifically robust but also practically applicable in real-world drug development settings. Her research has directly impacted the validation of surrogate endpoints, enhancing the efficiency of clinical studies in bone health. Through her focus on method validation and translational applications, Brunner has helped shape how biomarkers are integrated into late-stage clinical trials, making her a key figure in the advancement of precision medicine for skeletal diseases.
Research Focus
Key Achievements
Top Papers
- 1